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Potential for Q Fever Infection Among Travelers Returning from Iraq 
and the Netherlands
Summary
Increasing reports of Q fever among deployed U.S. military personnel due to endemic transmission in 
Iraq, as well as a large ongoing outbreak of Q fever in the Netherlands, may place travelers to these 
regions at risk for infection. Healthcare providers in the United States should consider Q fever in the 
differential diagnosis of persons with febrile illness, pneumonia or hepatitis who have recently been in 
Iraq or the Netherlands. Physicians are encouraged to submit samples for proper laboratory testing 
and contact the CDC for consultation if needed. Q fever cases in travelers should be promptly reported 
to proper authorities.
Background
Since Operation Iraqi Freedom commenced in 2003, over 200 cases of acute Q fever have been reported 
among U.S. military personnel deployed to Iraq. Since several of these cases were identified after 
returning to the U.S. or when they were no longer serving on active military duty, a heightened awareness 
for Q fever infection occurring in military personnel and civilian contractors is necessary to ensure prompt 
diagnosis and appropriate treatment. Q fever is endemic in the Middle East, and transmission may be 
influenced by hot, dusty conditions and livestock farming practices which may facilitate windborne spread.
In addition, a large number of Q fever cases have occurred in the Netherlands since 2007, with over 
3,700 human cases reported through March 2010. Infected dairy goat farms are believed to be the source 
of the outbreak, and the majority of human cases have been reported in the southern region of the 
country. To date, no imported cases of Q fever have been reported among American travelers returning 
home from the Netherlands.
Because travelers to these countries may have a higher likelihood of exposure to Q fever, the CDC 
Rickettsial Zoonoses Branch advises that physicians evaluate travelers returning from Iraq (particularly 
military personnel and civilian contractors) and the Netherlands with febrile illness, pneumonia or hepatitis 
for potential Q fever infection. Probable and confirmed cases should be reported to their local or state 
health department.
Q Fever Illness
Q fever is a zoonotic disease with both acute and chronic phases caused by the pathogen Coxiella 
burnetii. The primary mode of transmission to humans is inhalation of aerosols or dust contaminated by 
infected animals, most commonly cattle, sheep or goats. Direct animal contact is not required for 
transmission to occur as the organism may be spread by dust or wind. Infections via ingestion of 
contaminated dairy products and human-to-human transmission via sexual contact have rarely been 
reported. Q fever does occur in the United States, but fewer than 200 cases are reported annually.
Although asymptomatic infections may occur, an unexplained febrile illness, sometimes accompanied by 
pneumonia and/or hepatitis, is the most common clinical presentation. Illness onset typically occurs within 
2-3 weeks after exposure. The mortality rate for acute Q fever is low (1-2%), and the majority of persons 
with mild illness recover spontaneously within a few weeks although antibiotic treatment will shorten the 
duration of illness and lessen the risk of complications. Chronic Q fever is uncommon (<1% of acutely 
infected patients) but may cause life-threatening heart valve disease (endocarditis). Patients with pre­
existing heart valve disorders, pregnant women, and immunosuppressed persons are at increased risk for 
developing chronic Q fever. A Q fever vaccine is not commercially available in the United States and 
antibiotic prophylaxis is not recommended.
Recommendations
Physicians seeing a patient - particularly military personnel or a civilian contractor - who has an illness 
consistent with Q fever and who has traveled to Iraq or the Netherlands in the 30 days prior to illness 
onset should perform appropriate laboratory testing. Serologic testing should be requested for IgG and 
IgM antibodies against C. burnetii Phase I and II antigen using indirect immunofluorescence assay (IFA). 
PCR assays may be conducted on whole blood samples in the early stages of illness and prior to 
initiation of antibiotic therapy.
Serologic evidence of a fourfold rise in IgG Phase II antibody by indirect immunofluorescence assay (IFA) 
between paired sera taken 2-4 weeks apart is the gold standard for diagnosis of acute infection. A single 
high serum Phase II IgG titer by IFA (> 1:128) is considered evidence of probable infection. IgM testing 
alone should not be used for serodiagnosis as false positives may occur. Treatment should not be 
delayed while awaiting laboratory results. Doxycycline (100mg twice a day for 2-3 weeks) is the treatment 
of choice for acute Q fever.
Whenever possible, physicians should submit paired acute and convalescent serum samples to facilitate 
optimal diagnostic testing.
Type of sample




Acute - whole blood
1-7 days (prior to
PCR
antibiotic therapy)
Acute - serum 1-7 days
IFA for Phase I and II IgG and 
IgM
Convalescent - serum 21-35 days
IFA for Phase I and II IgG and 
IgM
Q fever is a nationally notifiable disease. A completed CDC Q fever Case Report Form should be 
submitted to the state health department for all probable and confirmed Q fever cases 
(http://www.cdc.gov/ncidod/dvrd/qfever/case_rep_fm.pdf). The patient's history of travel should be clearly 
noted on the case submission form.
For More Information:
• Additional information about Q fever is available at: 
http://www.bt.cdc.gov/agent/qfever/clinicians/index.asp.
• Call CDC's toll-free information line, 800-CDC-INFO (800-232-4636) TTY: (888) 232-6348, which is 
available 24 hours a day, every day.
• Contact the Rickettsial Zoonoses Branch at CDC: (404) 639-1075.
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